secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0000950170-24-018413
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q4 net loss $14.4M, cash $745M; KT-474 Phase 2 data due H1 2025
----------------------------------------------------------------------

- Net loss $14.4M in Q4, $147.0M for FY2023; collaboration revenue $47.9M Q4, $78.6M FY.
- Cash and investments $745M as of Jan 9, 2024, including $301M from equity offering; runway into H1 2027.
- KT-474 Phase 2 trials in HS and AD started; topline data expected H1 2025; $55M milestone from Sanofi.
- KT-621 STAT6 degrader Phase 1 expected H2 2024; KT-294 TYK2 Phase 1 expected H1 2025; data in 2025.
- Additional Phase 1 data for KT-333 (STAT3) and KT-253 (MDM2) expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000095017024018413/0000950170-24-018413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000095017024018413/kymr-20240222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-018413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer